title: Disappearance of fibrosis in secondary myelofibrosis after ruxolitinib treatment: new endpoint to achieve?
authors.affiliation: Department of Cellular Biotechnologies and Hematology, Sapienza University, Via Benevento 6, 00161, Rome, Italy.
authors.forename: Matteo
authors.initials: M
authors.lastname: Molica
authors.forename: Alessandra
authors.initials: A
authors.lastname: Serrao
authors.forename: Roberta
authors.initials: R
authors.lastname: Saracino
authors.forename: Irene
authors.initials: I
authors.lastname: Zacheo
authors.forename: Christof
authors.initials: C
authors.lastname: Stingone
authors.forename: Giuliana
authors.initials: G
authors.lastname: Alimena
authors.forename: Massimo
authors.initials: M
authors.lastname: Breccia
mesh_terms: D023381:Endpoint Determination / Q000592:standards*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009570:Nitriles; D055728:Primary Myelofibrosis / Q000175:diagnosis* / Q000188:drug therapy*; D011720:Pyrazoles / Q000627:therapeutic use*; D011743:Pyrimidines; D016896:Treatment Outcome
chemical_list: D009570:Nitriles; D011720:Pyrazoles; D011743:Pyrimidines; C540383:ruxolitinib